Tenuazonic acid-d13
Based on 1 Customer Validation
Tenuazonic acid-d13 is deuterium labeled Tenuazonic acid. Tenuazonic acid is a nonhost-selective mycotoxin belonging to the tetramic acids family. Tenuazonic acid inhibits protein biosynthesis on ribosomes by suppressing the release of new protein. Tenuazonic acid is acutely toxic, and oral LD50 is set between 81-186 mg/kg in rats and mice. Tenuazonic acid blocks electron transport beyond the primary quinone receptor (QA) by interacting with the D1 protein and is a photosystem II (PSII) inhibitor. In addition, Tenuazonic acid has antiviral effects on measles virus, enterovirus, respiratory virus and so on. Tenuazonic acid has an inhibitory effect on skin cancer.
For research use only. We do not sell to patients.
- Purity : 99.2%
- CAS No.: 2714417-30-6
- Formula: C10H2D13NO3
- Molecular Weight:210.31
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2714417-30-6
-
Unlabeled CAS 610-88-8
-
Appearance Solid
-
Molecular Weight 210.31
-
Formula C10H2D13NO3
-
Color White to off-white
-
SMILES
OC([C@@]([2H])(NC1=O)[C@@]([2H])(C([2H])([2H])[2H])C([2H])(C([2H])([2H])[2H])[2H])=C1C(C([2H])([2H])[2H])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Zhou B, et al. An evaluation of tenuazonic acid, a potential biobased herbicide in cotton. Pest Manag Sci. 2019 Mar 7. [Content Brief]
[3]. MILLER FA, et al. ANTIVIRAL ACTIVITY OF TENUAZONIC ACID. Nature. 1963 Dec 28;200:1338-9. [Content Brief]
[4]. Chen S, et al. Recent advances in tenuazonic acid as a potential herbicide. Pestic Biochem Physiol. 2017 Nov;143:252-257. [Content Brief]
[5]. Kumari A, et al. Tenuazonic acid-induced mycotoxicosis in an immunosuppressed mouse model and its prophylaxis with cinnamaldehyde. Chemosphere. 2024 Sep;363:142812. [Content Brief]
[6]. Antony M, et al. Inhibition of mouse skin tumor promotion by tenuazonic acid. Cancer Lett. 1991 Dec 9;61(1):21-5. [Content Brief]
[7]. Yun CS, Motoyama T, Osada H. Biosynthesis of the mycotoxin tenuazonic acid by a fungal NRPS-PKS hybrid enzyme. Nat Commun. 2015 Oct 27;6:8758. [Content Brief]
[8]. Gil-Serna J., et al. Encyclopedia of Food Microbiology. MYCOTOXINS | Toxicology. 2014 887–892.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)